The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | Prophylactic tocilizumab to mitigate CRS: results from a small cohort in the MajesTEC-1 trial
Cytokine release syndrome (CRS) is a common adverse event associated with the administration of bispecific monoclonal antibodies, including teclistamab, and tocilizumab is often used to manage this complication in patients. Maria Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, discusses the findings from a small cohort of patients in the Phase I/II MajesTEC-1 trial (NCT04557098) who were treated with prophylactic tocilizumab with the aim of mitigating CRS. Tocilizumab was given at least 4 hours prior to the administration of the first step-up dose, and this led to a significant reduction in the incidence of CRS and no grade 3 CRS events. Dr Mateos highlights that these findings are encouraging as the efficacy of the teclistamab treatment was not compromised by this prophylaxis. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
